Abstract

Epidermal growth factor receptor (EGFR) gene mutations are common in non-small cell lung cancer (NSCLC) patients characterized by female gender, a history of never smoking and an adenocarcinoma histology. These mutations usually predict favorable EGFR-tyrosine kinase inhibitors (TKIs) treatment efficacy and outcome. We report a non-smoking female with synchronous brain metastasis from pulmonary squamous cell carcinoma (SCC), which uncommonly harbored an EGFR exon 19 mutation and dramatically responded to EGFR TKI treatment. This case highlights that EGFR mutational analysis may be performed for pulmonary SCC patients that are East Asian females without a smoking history. The identification of EGFR mutations in pulmonary SCC may provide a treatment option using EGFR-TKIs.
Original languageEnglish
Pages (from-to)157-163
Number of pages7
Journal胸腔醫學
Volume30
Issue number3
Publication statusPublished - 2015

Fingerprint

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Squamous Cell Carcinoma
Exons
Lung
Mutation
Smoking
erbB-1 Genes
Non-Small Cell Lung Carcinoma
Histology
Adenocarcinoma
History
Neoplasm Metastasis
Brain
Therapeutics

Keywords

  • 表皮細胞生長因子接受器突變
  • 上皮細胞生長因素接收器-酪胺酸酶抑制劑
  • 肺麟狀細胞癌
  • epidermal growth factor receptor (EGFR) mutation
  • EGFR tyrosine kinase inhibitor (TKI)
  • pulmonary squamous cell carcinoma

Cite this

@article{ba22231251c441dc8295674fe2f8abe0,
title = "Pulmonary Squamous Cell Carcinoma Harboring EGFR Exon 19 Mutation Responded Dramatically to EGFR-TKI-A Case Report",
abstract = "Epidermal growth factor receptor (EGFR) gene mutations are common in non-small cell lung cancer (NSCLC) patients characterized by female gender, a history of never smoking and an adenocarcinoma histology. These mutations usually predict favorable EGFR-tyrosine kinase inhibitors (TKIs) treatment efficacy and outcome. We report a non-smoking female with synchronous brain metastasis from pulmonary squamous cell carcinoma (SCC), which uncommonly harbored an EGFR exon 19 mutation and dramatically responded to EGFR TKI treatment. This case highlights that EGFR mutational analysis may be performed for pulmonary SCC patients that are East Asian females without a smoking history. The identification of EGFR mutations in pulmonary SCC may provide a treatment option using EGFR-TKIs.",
keywords = "表皮細胞生長因子接受器突變, 上皮細胞生長因素接收器-酪胺酸酶抑制劑, 肺麟狀細胞癌, epidermal growth factor receptor (EGFR) mutation, EGFR tyrosine kinase inhibitor (TKI), pulmonary squamous cell carcinoma",
author = "Kai-Ling Lee and Sey-En Lin and Cheng-Ching Chung and Shih-Hsin Hsiao and Chi-Li Chung",
year = "2015",
language = "English",
volume = "30",
pages = "157--163",
journal = "胸腔醫學",
issn = "1023-9855",
publisher = "臺灣胸腔暨重症加護醫學會",
number = "3",

}

TY - JOUR

T1 - Pulmonary Squamous Cell Carcinoma Harboring EGFR Exon 19 Mutation Responded Dramatically to EGFR-TKI-A Case Report

AU - Lee, Kai-Ling

AU - Lin, Sey-En

AU - Chung, Cheng-Ching

AU - Hsiao, Shih-Hsin

AU - Chung, Chi-Li

PY - 2015

Y1 - 2015

N2 - Epidermal growth factor receptor (EGFR) gene mutations are common in non-small cell lung cancer (NSCLC) patients characterized by female gender, a history of never smoking and an adenocarcinoma histology. These mutations usually predict favorable EGFR-tyrosine kinase inhibitors (TKIs) treatment efficacy and outcome. We report a non-smoking female with synchronous brain metastasis from pulmonary squamous cell carcinoma (SCC), which uncommonly harbored an EGFR exon 19 mutation and dramatically responded to EGFR TKI treatment. This case highlights that EGFR mutational analysis may be performed for pulmonary SCC patients that are East Asian females without a smoking history. The identification of EGFR mutations in pulmonary SCC may provide a treatment option using EGFR-TKIs.

AB - Epidermal growth factor receptor (EGFR) gene mutations are common in non-small cell lung cancer (NSCLC) patients characterized by female gender, a history of never smoking and an adenocarcinoma histology. These mutations usually predict favorable EGFR-tyrosine kinase inhibitors (TKIs) treatment efficacy and outcome. We report a non-smoking female with synchronous brain metastasis from pulmonary squamous cell carcinoma (SCC), which uncommonly harbored an EGFR exon 19 mutation and dramatically responded to EGFR TKI treatment. This case highlights that EGFR mutational analysis may be performed for pulmonary SCC patients that are East Asian females without a smoking history. The identification of EGFR mutations in pulmonary SCC may provide a treatment option using EGFR-TKIs.

KW - 表皮細胞生長因子接受器突變

KW - 上皮細胞生長因素接收器-酪胺酸酶抑制劑

KW - 肺麟狀細胞癌

KW - epidermal growth factor receptor (EGFR) mutation

KW - EGFR tyrosine kinase inhibitor (TKI)

KW - pulmonary squamous cell carcinoma

M3 - Article

VL - 30

SP - 157

EP - 163

JO - 胸腔醫學

JF - 胸腔醫學

SN - 1023-9855

IS - 3

ER -